ESC Pocket Guidelines vs Residipok

The ESC Pocket Guidelines app now contains the following ESC Pocket Guidelines: ESC Guidelines and documents published in 2025 Cardiovascular disease and pregnancy (Guidelines) Mental health and cardiovascular disease (Consensus Statement) Myocarditis and pericarditis (Guidelines) Valvular heart disease (Joint Guidelines with EACTS) Focused update of the 2019 dyslipidaemias guidelines ESC Guidelines published in 2024 Elevated blood pressure and hypertension Atrial fibrillation Chronic coronary syndromes Peripheral arterial and aortic diseases ESC Guidelines and documents published in 2023 Acute coronary syndromes Cardiomyopathies Cardiovascular disease in diabetes Endocarditis Focused update of the 2021 heart failure guidelines The ESC Pocket Guidelines app also contains interactive tools in the form of algorithms. Additional features: Perform „full text", „index" or „filtered" searches through the entire downloaded content of the app, bookmarks and the notes. Bookmark specific sections or create a personal note and access bookmarks and notes from the „Library“ section. Share links to specific areas of the app via communication channels, e.g. AirDrop, Mail, LinkedIn, Twitter, WhatsApp, and many others. Print pages. Please follow the link below to register for a new MyESC account: https://escol.escardio.org/MyESC/login.aspx

Residipok is a pocket reference for licensed healthcare professionals, trainees, and medical students of accredited health-professions programs. TWO MODULES (v0.4) • MIC Lookup Choose a bacterium and an antibiotic to see the EUCAST v16.0 (2026) Clinical Breakpoint thresholds — S, I, R bands by clinical context (systemic, meningitis, urinary, high-dose). Enter an MIC value to categorise it. Special states clearly labelled when no breakpoint is published or the organism is intrinsically resistant. Built especially for pan-resistance scenarios where every threshold matters. • ESC Guideline Reference Structured Class / Level of Evidence summaries of recent ESC cardiology guidelines, covering acute coronary syndromes, heart failure, atrial fibrillation, hypertension, endocarditis, cardiomyopathies, valvular disease, pulmonary hypertension and embolism, peripheral arterial disease, dyslipidaemia, prevention, pregnancy, syncope, supraventricular tachycardia, and more. Each recommendation card links back to the original guideline on escardio.org. IMPORTANT — REFERENCE ONLY • Residipok is NOT a medical device. • It does NOT diagnose, treat, cure, or prevent disease. • It is NOT a substitute for clinical judgement or for the original published guideline / breakpoint table. • Always verify against the current EUCAST table and the latest ESC document before clinical reporting. Requires confirmation of HCP / trainee status on first launch. Sign-in by email, Apple, or Google. Sources: EUCAST Clinical Breakpoint Tables v16.0 (2026); European Society of Cardiology Clinical Practice Guidelines (2018–2024).